Elicio Therapeutics Q2 EPS $(0.64) Beats $(0.96) Estimate
Portfolio Pulse from Benzinga Newsdesk
Elicio Therapeutics (NASDAQ:ELTX) reported a Q2 EPS of $(0.64), beating the analyst consensus estimate of $(0.96) by 33.33%. This represents a 75.48% improvement over the losses of $(2.61) per share from the same period last year.
August 13, 2024 | 8:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Elicio Therapeutics reported a Q2 EPS of $(0.64), beating the analyst consensus estimate of $(0.96) by 33.33%. This is a significant improvement over the losses of $(2.61) per share from the same period last year, indicating better-than-expected financial performance.
The better-than-expected EPS and significant year-over-year improvement suggest positive financial performance, likely leading to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100